Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Tokyo and Basking Ridge, NJ– (April 4, 2019)– Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials